[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Immix Biopharma, Inc. (IMMX) filed a Form 4 on 23-Jun-2025 disclosing an equity award to insider Gabriel S. Morris, who serves as Director and Chief Financial Officer.

On 20-Jun-2025 Mr. Morris received 340,000 stock options with a $2.24 exercise price. The options vest in 48 equal monthly instalments and expire on 20-Jun-2035, signalling a long-term incentive structure tied to continued service.

Post-grant, Mr. Morris reports beneficial ownership of:

• 288,059 common shares held directly.
• 270,844 common shares held indirectly through Alwaysraise LLC.
• 24,141 common shares held indirectly through Alwaysraise Ventures I LP.
• 340,000 option shares newly awarded.

This totals 582,,,,,,ционной share options and 582,,,�直接持有 shares.

The filing shows no open-market purchases or sales; the transaction code “A” denotes an award. While the option grant introduces potential future dilution, it also aligns executive incentives with shareholder value creation over a ten-year horizon.

Positive

• Significant insider equity ownership of roughly 582 k shares aligns management incentives with shareholders.

Negative

• Grant of 340,000 stock options adds potential future dilution and option overhang.

Insights

Corporate Governance Expert

TL;DR: Routine option grant; strengthens retention, modest dilution; neutral governance impact.

The Form 4 documents a standard compensation action. A 340 k option package with four-year vesting is common for dual Director/CFO roles in micro-cap biotech. The long vesting horizon incentivises continuity and aligns Mr. Morris with equity performance. There is no evidence of opportunistic timing or 10b5-1 plan usage. Without information on total shares outstanding, dilution significance cannot be quantified, but the single-digit nature of the award relative to typical micro-cap floats suggests limited impact. Overall, governance implications are neutral.

Portfolio Manager

TL;DR: Neutral for valuation; option strike near market, no cash outflow, small potential overhang.

This filing neither signals insider buying nor selling—merely compensation. The $2.24 strike likely approximates the 20-Jun-2025 market price, so the award is not immediately in-the-money. Investors should watch for cumulative option overhang but, on its own, 340 k options are unlikely to move the share-count needle materially. The insider’s 582 k share exposure (direct + indirect) reflects meaningful skin-in-the-game, a modest positive for alignment. Net impact to valuation models or near-term trading dynamics is negligible.

06/23/2025 - 04:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Gabriel S

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								288,059	D
Common Stock								270,844	I	See footnote(1)
Common Stock								24,141	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.24	06/20/2025		A		340,000		(3)	06/20/2035	Common Stock	340,000	$0.00	340,000	D

Explanation of Responses:

1. Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein.

2. Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC ("Alwaysraise Ventures"), the general partner of Alwaysraise Ventures I, LP. ("AVILP") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein.

3. The Stock Option will vest in forty-eight (48) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Gabriel Morris	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did IMMX CFO Gabriel S. Morris receive?

Mr. Morris was granted 340,000 stock options on 20-Jun-2025.

What is the exercise price of the new IMMX options?

The options carry a $2.24 per-share exercise price.

When will the IMMX options vest?

They vest in 48 equal monthly instalments following the 20-Jun-2025 grant date.

What is Gabriel Morris’s total IMMX share ownership after the filing?

He reports 288,059 direct shares, 294,985 indirect shares, and 340,000 option shares.

Does the Form 4 indicate a sale or purchase of existing shares?

No. The filing only shows an equity award (code "A"); there were no market purchases or sales.

Is the transaction linked to a Rule 10b5-1 trading plan?

The checkbox for a Rule 10b5-1 plan is unchecked, so no such plan is indicated.